Clinical Edge Journal Scan

Key clinical point: Teriparatide may have better therapeutic effects than denosumab in glucocorticoid-induced osteoporosis (GIO) patients previously treated with bisphosphonates.

Major finding: Teriparatide group showed a significantly greater improvement in the bone mineral density (BMD) of lumbar spine (P less than .01) and femoral neck (P less than .05) vs. denosumab group at 12 months, but not at 24 months. At 24 months, BMD of lumbar spine had significantly increased from baseline in both the groups, whereas BMD of femoral neck had increased only in the teriparatide group.

Study details: A prospective, open-label, nonrandomized, single-center study including 47 patients with GIO assigned to either teriparatide group (n = 23) or denosumab group (n = 24).

Disclosures: The study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Hirooka Y et al. Bone Rep. 2020 Jul 4. doi: 10.1016/j.bonr.2020.100293.

Key clinical point: Teriparatide may have better therapeutic effects than denosumab in glucocorticoid-induced osteoporosis (GIO) patients previously treated with bisphosphonates.

Major finding: Teriparatide group showed a significantly greater improvement in the bone mineral density (BMD) of lumbar spine (P less than .01) and femoral neck (P less than .05) vs. denosumab group at 12 months, but not at 24 months. At 24 months, BMD of lumbar spine had significantly increased from baseline in both the groups, whereas BMD of femoral neck had increased only in the teriparatide group.

Study details: A prospective, open-label, nonrandomized, single-center study including 47 patients with GIO assigned to either teriparatide group (n = 23) or denosumab group (n = 24).

Disclosures: The study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Hirooka Y et al. Bone Rep. 2020 Jul 4. doi: 10.1016/j.bonr.2020.100293.

Key clinical point: Teriparatide may have better therapeutic effects than denosumab in glucocorticoid-induced osteoporosis (GIO) patients previously treated with bisphosphonates.

Major finding: Teriparatide group showed a significantly greater improvement in the bone mineral density (BMD) of lumbar spine (P less than .01) and femoral neck (P less than .05) vs. denosumab group at 12 months, but not at 24 months. At 24 months, BMD of lumbar spine had significantly increased from baseline in both the groups, whereas BMD of femoral neck had increased only in the teriparatide group.

Study details: A prospective, open-label, nonrandomized, single-center study including 47 patients with GIO assigned to either teriparatide group (n = 23) or denosumab group (n = 24).

Disclosures: The study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Hirooka Y et al. Bone Rep. 2020 Jul 4. doi: 10.1016/j.bonr.2020.100293.

Key clinical point: Psoriatic arthritis (PsA) is associated with the risk for low bone mineral density (BMD), but this association is partially mediated by treatment with methotrexate or ciclosporin. Psoriasis excluding PsA in the absence of a secondary condition is not a risk factor for osteoporosis.

Major finding: PsA was associated with low BMD (β-coefficient = −0.014; P = .0006). However, the association became nonsignificant when patients were treated with methotrexate or ciclosporin (β-coefficient = −0.005; P = .28). Psoriasis without arthritis was not associated with low BMD or osteoporosis.

Study details: The data come from a cross-sectional study of 432,513 participants from the UK Biobank dataset.

Disclosures: The study was supported by the Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholars of China and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Xia J et al. Ann Rheum Dis. 2020 Jul 31. doi: 10.1136/annrheumdis-2020-217892.

Key clinical point: Psoriatic arthritis (PsA) is associated with the risk for low bone mineral density (BMD), but this association is partially mediated by treatment with methotrexate or ciclosporin. Psoriasis excluding PsA in the absence of a secondary condition is not a risk factor for osteoporosis.

Major finding: PsA was associated with low BMD (β-coefficient = −0.014; P = .0006). However, the association became nonsignificant when patients were treated with methotrexate or ciclosporin (β-coefficient = −0.005; P = .28). Psoriasis without arthritis was not associated with low BMD or osteoporosis.

Study details: The data come from a cross-sectional study of 432,513 participants from the UK Biobank dataset.

Disclosures: The study was supported by the Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholars of China and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Xia J et al. Ann Rheum Dis. 2020 Jul 31. doi: 10.1136/annrheumdis-2020-217892.

Key clinical point: Psoriatic arthritis (PsA) is associated with the risk for low bone mineral density (BMD), but this association is partially mediated by treatment with methotrexate or ciclosporin. Psoriasis excluding PsA in the absence of a secondary condition is not a risk factor for osteoporosis.

Major finding: PsA was associated with low BMD (β-coefficient = −0.014; P = .0006). However, the association became nonsignificant when patients were treated with methotrexate or ciclosporin (β-coefficient = −0.005; P = .28). Psoriasis without arthritis was not associated with low BMD or osteoporosis.

Study details: The data come from a cross-sectional study of 432,513 participants from the UK Biobank dataset.

Disclosures: The study was supported by the Zhejiang Provincial Natural Science Foundation for Distinguished Young Scholars of China and the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Xia J et al. Ann Rheum Dis. 2020 Jul 31. doi: 10.1136/annrheumdis-2020-217892.

Key clinical point: Treatment with abaloparatide is associated with a transient increase in heart rate (HR) and a small decrease in post-dose blood pressure (BP) in postmenopausal women with osteoporosis.

Major finding: Abaloparatide showed a significantly higher mean HR change from pretreatment to 1 hour posttreatment on day 1 vs. placebo (mean [standard deviation]: 7.9 [8.5] vs. 1.2 [7.1] beats per minute; P less than .0001). Abaloparatide showed a significantly higher change in systolic and diastolic blood pressure from pre-dose to 1 hour post-dose vs. placebo (−2.7/−3.6 vs. −1.5/−2.3 mmHg; P less than .05). These changes were not associated with an increased risk of serious cardiac adverse events, major adverse cardiovascular events, and heart failure.

Study details: The findings are based on a post-hoc analysis from the ACTIVE and ACTIVExtend trials including 2,460 postmenopausal women with osteoporosis.

Disclosures: Dr. Felicia Cosman, Dr. Steven R Cummings, Dr. Linda R Peterson, and Dr. Dwight A Towler consulted for/received research grants from pharmaceutical companies/research institutes including Amgen; Radius Health, Inc.; and the National Institutes of Health. Dr. Bruce Mitlak and Dr. Yamei Wang are employees of and hold equity in Radius Health, Inc.

Source: Cosman F et al. J Clin Endocrinol Metab. 2020 Jul 13. doi: 10.1210/clinem/dgaa450.

Key clinical point: Treatment with abaloparatide is associated with a transient increase in heart rate (HR) and a small decrease in post-dose blood pressure (BP) in postmenopausal women with osteoporosis.

Major finding: Abaloparatide showed a significantly higher mean HR change from pretreatment to 1 hour posttreatment on day 1 vs. placebo (mean [standard deviation]: 7.9 [8.5] vs. 1.2 [7.1] beats per minute; P less than .0001). Abaloparatide showed a significantly higher change in systolic and diastolic blood pressure from pre-dose to 1 hour post-dose vs. placebo (−2.7/−3.6 vs. −1.5/−2.3 mmHg; P less than .05). These changes were not associated with an increased risk of serious cardiac adverse events, major adverse cardiovascular events, and heart failure.

Study details: The findings are based on a post-hoc analysis from the ACTIVE and ACTIVExtend trials including 2,460 postmenopausal women with osteoporosis.

Disclosures: Dr. Felicia Cosman, Dr. Steven R Cummings, Dr. Linda R Peterson, and Dr. Dwight A Towler consulted for/received research grants from pharmaceutical companies/research institutes including Amgen; Radius Health, Inc.; and the National Institutes of Health. Dr. Bruce Mitlak and Dr. Yamei Wang are employees of and hold equity in Radius Health, Inc.

Source: Cosman F et al. J Clin Endocrinol Metab. 2020 Jul 13. doi: 10.1210/clinem/dgaa450.

Key clinical point: Treatment with abaloparatide is associated with a transient increase in heart rate (HR) and a small decrease in post-dose blood pressure (BP) in postmenopausal women with osteoporosis.

Major finding: Abaloparatide showed a significantly higher mean HR change from pretreatment to 1 hour posttreatment on day 1 vs. placebo (mean [standard deviation]: 7.9 [8.5] vs. 1.2 [7.1] beats per minute; P less than .0001). Abaloparatide showed a significantly higher change in systolic and diastolic blood pressure from pre-dose to 1 hour post-dose vs. placebo (−2.7/−3.6 vs. −1.5/−2.3 mmHg; P less than .05). These changes were not associated with an increased risk of serious cardiac adverse events, major adverse cardiovascular events, and heart failure.

Study details: The findings are based on a post-hoc analysis from the ACTIVE and ACTIVExtend trials including 2,460 postmenopausal women with osteoporosis.

Disclosures: Dr. Felicia Cosman, Dr. Steven R Cummings, Dr. Linda R Peterson, and Dr. Dwight A Towler consulted for/received research grants from pharmaceutical companies/research institutes including Amgen; Radius Health, Inc.; and the National Institutes of Health. Dr. Bruce Mitlak and Dr. Yamei Wang are employees of and hold equity in Radius Health, Inc.

Source: Cosman F et al. J Clin Endocrinol Metab. 2020 Jul 13. doi: 10.1210/clinem/dgaa450.

Key clinical point: Women with a previous fracture or who had an inflammatory rheumatic disease were more likely to start antiosteoporotic drugs (AODs) within 1 year from glucocorticoid (GC) initiation. However, the proportions starting an AOD were much lower than clinically indicated.

Major finding: Women with vs. without previous fracture were twice as likely to start an AOD within 1 year after initiating GC treatment, but the cumulative incidences were low: 9.1% vs. 4.6%, respectively. Women with a diagnosis of rheumatoid arthritis or another inflammatory rheumatic disease were more likely to start an AOD compared with women with other diagnoses.

Study details: This Norwegian population-based study evaluated the initiation of osteoporosis prophylaxis with AOD in women starting treatment with oral GC (n=105,477; age, 55 years or older).

Disclosures: Open Access funding was provided by the University of Bergen. Astrid Lunde is involved in the Denosumab Global Safety Study. Department of Clinical Epidemiology, Aarhus University receives an institutional research funding from several pharmaceutical companies, some of which manufacture AOD. None of these companies was involved in the current study. Vera Ehrenstein is a salaried employee of the Aarhus University. Ellen M Apalset, Mari Hoff, and Grethe S Tell declared no conflicts of interest.

Source: Apalset EM et al. Arch Osteoporos. 2020 Aug 5. doi: 10.1007/s11657-020-00783-8.

Key clinical point: Women with a previous fracture or who had an inflammatory rheumatic disease were more likely to start antiosteoporotic drugs (AODs) within 1 year from glucocorticoid (GC) initiation. However, the proportions starting an AOD were much lower than clinically indicated.

Major finding: Women with vs. without previous fracture were twice as likely to start an AOD within 1 year after initiating GC treatment, but the cumulative incidences were low: 9.1% vs. 4.6%, respectively. Women with a diagnosis of rheumatoid arthritis or another inflammatory rheumatic disease were more likely to start an AOD compared with women with other diagnoses.

Study details: This Norwegian population-based study evaluated the initiation of osteoporosis prophylaxis with AOD in women starting treatment with oral GC (n=105,477; age, 55 years or older).

Disclosures: Open Access funding was provided by the University of Bergen. Astrid Lunde is involved in the Denosumab Global Safety Study. Department of Clinical Epidemiology, Aarhus University receives an institutional research funding from several pharmaceutical companies, some of which manufacture AOD. None of these companies was involved in the current study. Vera Ehrenstein is a salaried employee of the Aarhus University. Ellen M Apalset, Mari Hoff, and Grethe S Tell declared no conflicts of interest.

Source: Apalset EM et al. Arch Osteoporos. 2020 Aug 5. doi: 10.1007/s11657-020-00783-8.

Key clinical point: Women with a previous fracture or who had an inflammatory rheumatic disease were more likely to start antiosteoporotic drugs (AODs) within 1 year from glucocorticoid (GC) initiation. However, the proportions starting an AOD were much lower than clinically indicated.

Major finding: Women with vs. without previous fracture were twice as likely to start an AOD within 1 year after initiating GC treatment, but the cumulative incidences were low: 9.1% vs. 4.6%, respectively. Women with a diagnosis of rheumatoid arthritis or another inflammatory rheumatic disease were more likely to start an AOD compared with women with other diagnoses.

Study details: This Norwegian population-based study evaluated the initiation of osteoporosis prophylaxis with AOD in women starting treatment with oral GC (n=105,477; age, 55 years or older).

Disclosures: Open Access funding was provided by the University of Bergen. Astrid Lunde is involved in the Denosumab Global Safety Study. Department of Clinical Epidemiology, Aarhus University receives an institutional research funding from several pharmaceutical companies, some of which manufacture AOD. None of these companies was involved in the current study. Vera Ehrenstein is a salaried employee of the Aarhus University. Ellen M Apalset, Mari Hoff, and Grethe S Tell declared no conflicts of interest.

Source: Apalset EM et al. Arch Osteoporos. 2020 Aug 5. doi: 10.1007/s11657-020-00783-8.

Key clinical point: Delaying denosumab doses by more than 16 weeks is associated with an increased risk of vertebral fracture in patients with osteoporosis vs. on-time injections. However, evidence is insufficient to conclude that fracture risk is increased at other anatomical sites with a long delay.

Major finding: Compared with on-time injections (within 4 weeks after the recommended date), short delay (by 4-16 weeks) had a hazard ratio (HR) of 1.03 and long delay (by more than 16 weeks) an HR of 1.44 (P for trend = .093) for composite fracture. For vertebral fractures, short delay had an HR of 1.48 and long delay an HR of 3.91 (P for trend = .005).

Study details: This U.K. population-based cohort study included 2,594 patients (age, 45 years or older) who initiated denosumab therapy for osteoporosis.

Disclosures: The study was supported by a grant from the National Institutes of Health and by the internal resources from the National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation (Beijing) and Xiangya Hospital, Central South University. The authors declared no conflicts of interest in relation to the subject of the study. Three of the authors reported receiving grants from 1 or more pharma companies, outside the submitted work.

Source: Lyu H et al. Ann Intern Med. 2020 Jul 28. doi: 10.7326/M20-0882.

Key clinical point: Delaying denosumab doses by more than 16 weeks is associated with an increased risk of vertebral fracture in patients with osteoporosis vs. on-time injections. However, evidence is insufficient to conclude that fracture risk is increased at other anatomical sites with a long delay.

Major finding: Compared with on-time injections (within 4 weeks after the recommended date), short delay (by 4-16 weeks) had a hazard ratio (HR) of 1.03 and long delay (by more than 16 weeks) an HR of 1.44 (P for trend = .093) for composite fracture. For vertebral fractures, short delay had an HR of 1.48 and long delay an HR of 3.91 (P for trend = .005).

Study details: This U.K. population-based cohort study included 2,594 patients (age, 45 years or older) who initiated denosumab therapy for osteoporosis.

Disclosures: The study was supported by a grant from the National Institutes of Health and by the internal resources from the National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation (Beijing) and Xiangya Hospital, Central South University. The authors declared no conflicts of interest in relation to the subject of the study. Three of the authors reported receiving grants from 1 or more pharma companies, outside the submitted work.

Source: Lyu H et al. Ann Intern Med. 2020 Jul 28. doi: 10.7326/M20-0882.

Key clinical point: Delaying denosumab doses by more than 16 weeks is associated with an increased risk of vertebral fracture in patients with osteoporosis vs. on-time injections. However, evidence is insufficient to conclude that fracture risk is increased at other anatomical sites with a long delay.

Major finding: Compared with on-time injections (within 4 weeks after the recommended date), short delay (by 4-16 weeks) had a hazard ratio (HR) of 1.03 and long delay (by more than 16 weeks) an HR of 1.44 (P for trend = .093) for composite fracture. For vertebral fractures, short delay had an HR of 1.48 and long delay an HR of 3.91 (P for trend = .005).

Study details: This U.K. population-based cohort study included 2,594 patients (age, 45 years or older) who initiated denosumab therapy for osteoporosis.

Disclosures: The study was supported by a grant from the National Institutes of Health and by the internal resources from the National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation (Beijing) and Xiangya Hospital, Central South University. The authors declared no conflicts of interest in relation to the subject of the study. Three of the authors reported receiving grants from 1 or more pharma companies, outside the submitted work.

Source: Lyu H et al. Ann Intern Med. 2020 Jul 28. doi: 10.7326/M20-0882.

Key clinical point: Postmenopausal women with osteoporosis have a lower concentration of serum magnesium (Mg). However, the association between serum Mg concentration and osteopenia is not significant.

Major finding: Serum Mg concentration was lower in postmenopausal women with osteoporosis vs. healthy controls (standardized mean difference [SMD], −0.56; 95% confidence interval [CI], −1.02 to −0.09). However, the concentration of serum Mg did not differ between those with osteopenia and healthy controls (SMD, −0.30; 95% CI, −0.69 to 0.09).

Study details: A meta-analysis of 11 studies including 2,776 postmenopausal women.

Disclosures: The study was financially supported through grants from the Natural Science Foundation of Shandong Province, the Medical and Health Science and Technology Development Project of Shandong Province, the Clinical Medical Science and Technology Innovation Program of the Jinan Science and Technology Bureau, and the Traditional Chinese Medicine Technology Development Plan of Shandong Province. The authors declared no conflicts of interest.

Source: Chang J et al. Front Med. 2020 Aug 4. doi: 10.3389/fmed.2020.00381.

Key clinical point: Postmenopausal women with osteoporosis have a lower concentration of serum magnesium (Mg). However, the association between serum Mg concentration and osteopenia is not significant.

Major finding: Serum Mg concentration was lower in postmenopausal women with osteoporosis vs. healthy controls (standardized mean difference [SMD], −0.56; 95% confidence interval [CI], −1.02 to −0.09). However, the concentration of serum Mg did not differ between those with osteopenia and healthy controls (SMD, −0.30; 95% CI, −0.69 to 0.09).

Study details: A meta-analysis of 11 studies including 2,776 postmenopausal women.

Disclosures: The study was financially supported through grants from the Natural Science Foundation of Shandong Province, the Medical and Health Science and Technology Development Project of Shandong Province, the Clinical Medical Science and Technology Innovation Program of the Jinan Science and Technology Bureau, and the Traditional Chinese Medicine Technology Development Plan of Shandong Province. The authors declared no conflicts of interest.

Source: Chang J et al. Front Med. 2020 Aug 4. doi: 10.3389/fmed.2020.00381.

Key clinical point: Postmenopausal women with osteoporosis have a lower concentration of serum magnesium (Mg). However, the association between serum Mg concentration and osteopenia is not significant.

Major finding: Serum Mg concentration was lower in postmenopausal women with osteoporosis vs. healthy controls (standardized mean difference [SMD], −0.56; 95% confidence interval [CI], −1.02 to −0.09). However, the concentration of serum Mg did not differ between those with osteopenia and healthy controls (SMD, −0.30; 95% CI, −0.69 to 0.09).

Study details: A meta-analysis of 11 studies including 2,776 postmenopausal women.

Disclosures: The study was financially supported through grants from the Natural Science Foundation of Shandong Province, the Medical and Health Science and Technology Development Project of Shandong Province, the Clinical Medical Science and Technology Innovation Program of the Jinan Science and Technology Bureau, and the Traditional Chinese Medicine Technology Development Plan of Shandong Province. The authors declared no conflicts of interest.

Source: Chang J et al. Front Med. 2020 Aug 4. doi: 10.3389/fmed.2020.00381.

Key clinical point: Early treatment with romosozumab significantly improves bone mineral density (BMD) of the lumbar spine (LS) in postmenopausal osteoporosis. The response is attenuated by previous treatment and predicted by early changes in bone turnover markers.

Major finding: At 6 months of romosozumab induction, the naïve group had the highest increase in LS BMD (13.6%; P less than .001), followed by teriparatide (8.7%; P less than .001), bisphosphonates (7.5%; P less than .001), and denosumab (3.6%; P less than .001) groups. Serum N-terminal type I procollagen propeptide value at baseline and 1 month and isoform 5b of tartrate-resistant acid phosphatase value at baseline and its percentage change at 1 and 6 months were significant predictors (P less than .05) of LS BMD change at 6 months.

Study details: The data come from a prospective, observational, multicenter study of postmenopausal patients with osteoporosis who were either treatment naïve and received romosozumab (n = 37) or were previously treated with bisphosphonates (n = 33), denosumab (n = 45), or teriparatide (n = 15) and switched to romosozumab.

Disclosures: The study received no commercial funding. Dr. Kosuke Ebina and Dr. Ken Nakata are affiliated with the Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, which is supported by Taisho. Dr. Kosuke Ebina, Dr. Makoto Hirao, Dr. Hideki Tsuboi, Dr. Yoshio Nagayama, and Dr. Masafumi Kashii have received research grants from various pharmaceutical companies. The remaining authors reported no conflicts of interest.

Source: Ebina K et al. Bone. 2020 Aug 7. doi: 10.1016/j.bone.2020.115574.

Key clinical point: Early treatment with romosozumab significantly improves bone mineral density (BMD) of the lumbar spine (LS) in postmenopausal osteoporosis. The response is attenuated by previous treatment and predicted by early changes in bone turnover markers.

Major finding: At 6 months of romosozumab induction, the naïve group had the highest increase in LS BMD (13.6%; P less than .001), followed by teriparatide (8.7%; P less than .001), bisphosphonates (7.5%; P less than .001), and denosumab (3.6%; P less than .001) groups. Serum N-terminal type I procollagen propeptide value at baseline and 1 month and isoform 5b of tartrate-resistant acid phosphatase value at baseline and its percentage change at 1 and 6 months were significant predictors (P less than .05) of LS BMD change at 6 months.

Study details: The data come from a prospective, observational, multicenter study of postmenopausal patients with osteoporosis who were either treatment naïve and received romosozumab (n = 37) or were previously treated with bisphosphonates (n = 33), denosumab (n = 45), or teriparatide (n = 15) and switched to romosozumab.

Disclosures: The study received no commercial funding. Dr. Kosuke Ebina and Dr. Ken Nakata are affiliated with the Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, which is supported by Taisho. Dr. Kosuke Ebina, Dr. Makoto Hirao, Dr. Hideki Tsuboi, Dr. Yoshio Nagayama, and Dr. Masafumi Kashii have received research grants from various pharmaceutical companies. The remaining authors reported no conflicts of interest.

Source: Ebina K et al. Bone. 2020 Aug 7. doi: 10.1016/j.bone.2020.115574.

Key clinical point: Early treatment with romosozumab significantly improves bone mineral density (BMD) of the lumbar spine (LS) in postmenopausal osteoporosis. The response is attenuated by previous treatment and predicted by early changes in bone turnover markers.

Major finding: At 6 months of romosozumab induction, the naïve group had the highest increase in LS BMD (13.6%; P less than .001), followed by teriparatide (8.7%; P less than .001), bisphosphonates (7.5%; P less than .001), and denosumab (3.6%; P less than .001) groups. Serum N-terminal type I procollagen propeptide value at baseline and 1 month and isoform 5b of tartrate-resistant acid phosphatase value at baseline and its percentage change at 1 and 6 months were significant predictors (P less than .05) of LS BMD change at 6 months.

Study details: The data come from a prospective, observational, multicenter study of postmenopausal patients with osteoporosis who were either treatment naïve and received romosozumab (n = 37) or were previously treated with bisphosphonates (n = 33), denosumab (n = 45), or teriparatide (n = 15) and switched to romosozumab.

Disclosures: The study received no commercial funding. Dr. Kosuke Ebina and Dr. Ken Nakata are affiliated with the Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, which is supported by Taisho. Dr. Kosuke Ebina, Dr. Makoto Hirao, Dr. Hideki Tsuboi, Dr. Yoshio Nagayama, and Dr. Masafumi Kashii have received research grants from various pharmaceutical companies. The remaining authors reported no conflicts of interest.

Source: Ebina K et al. Bone. 2020 Aug 7. doi: 10.1016/j.bone.2020.115574.

Key clinical point: Diets rich in pro-inflammatory components may increase the risk of osteoporosis, fractures, and lower bone mineral density (BMD) of lumbar spine and total hip.

Major finding: Dietary Inflammatory Index (DII) was negatively linked with BMD of lumbar spine (odds ratios [OR], 0.990; P = .144) and total hip (OR, 0.995; P = .392). The highest category of DII was associated with an elevated risk of osteoporosis (pooled effect size [ES], 1.31; 95% confidence interval [CI], 1.16-1.48) and fractures (pooled ES, 1.26; 95% CI, 1.03-1.59) compared with the lowest category of DII.

Study details: A meta-analysis of 11 studies (4 cohort, 1 case-control, and 6 cross-sectional) involving 127,769 participants.

Disclosures: The study was supported by the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Fang Y et al. Osteoporos Int. 2020 Aug 1. doi: 10.1007/s00198-020-05578-8.

Key clinical point: Diets rich in pro-inflammatory components may increase the risk of osteoporosis, fractures, and lower bone mineral density (BMD) of lumbar spine and total hip.

Major finding: Dietary Inflammatory Index (DII) was negatively linked with BMD of lumbar spine (odds ratios [OR], 0.990; P = .144) and total hip (OR, 0.995; P = .392). The highest category of DII was associated with an elevated risk of osteoporosis (pooled effect size [ES], 1.31; 95% confidence interval [CI], 1.16-1.48) and fractures (pooled ES, 1.26; 95% CI, 1.03-1.59) compared with the lowest category of DII.

Study details: A meta-analysis of 11 studies (4 cohort, 1 case-control, and 6 cross-sectional) involving 127,769 participants.

Disclosures: The study was supported by the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Fang Y et al. Osteoporos Int. 2020 Aug 1. doi: 10.1007/s00198-020-05578-8.

Key clinical point: Diets rich in pro-inflammatory components may increase the risk of osteoporosis, fractures, and lower bone mineral density (BMD) of lumbar spine and total hip.

Major finding: Dietary Inflammatory Index (DII) was negatively linked with BMD of lumbar spine (odds ratios [OR], 0.990; P = .144) and total hip (OR, 0.995; P = .392). The highest category of DII was associated with an elevated risk of osteoporosis (pooled effect size [ES], 1.31; 95% confidence interval [CI], 1.16-1.48) and fractures (pooled ES, 1.26; 95% CI, 1.03-1.59) compared with the lowest category of DII.

Study details: A meta-analysis of 11 studies (4 cohort, 1 case-control, and 6 cross-sectional) involving 127,769 participants.

Disclosures: The study was supported by the National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Fang Y et al. Osteoporos Int. 2020 Aug 1. doi: 10.1007/s00198-020-05578-8.

Key clinical point: Postmenopausal osteoporotic women with low body mass index (BMI) have a higher risk of developing osteosarcopenia. Moreover, appropriate assessments, including the presence of comorbidities, will help in identifying patients at a greater risk of developing osteosarcopenia, especially for patients aged 65-74 years.

Major finding: Patients with osteosarcopenia had a higher risk of frailty vs. those with osteoporosis alone (odds ratio [OR], 2.33; P = .028). BMI (per 1 kg/m² decrease) seemed to be the strongest factor associated with osteosarcopenia risk (adjusted OR [aOR], 1.71; P less than .01). In patients aged 65-74 years, estimated glomerular filtration rate (per 10 mL/min/1.73m² decrease) and glycated hemoglobin (per 1% decrease) were identified as independent predictors of osteosarcopenia (aOR, 1.75; P = .01 and aOR, 5.01; P = .01, respectively).

Study details: The data come from a retrospective study of 276 patients with postmenopausal osteoporosis (osteoporosis alone: n=222 and osteosarcopenia: n=54).

Disclosures: The study was supported by grants awarded to Dr. Koji Ishikawa by KAKENHI and Grant of Japan Orthopaedics and Traumatology Research Foundation. The authors declared no conflicts of interest.

Source: Okamura H et al. PLoS One. 2020 Aug 7. doi: 10.1371/journal.pone.0237454.

Key clinical point: Postmenopausal osteoporotic women with low body mass index (BMI) have a higher risk of developing osteosarcopenia. Moreover, appropriate assessments, including the presence of comorbidities, will help in identifying patients at a greater risk of developing osteosarcopenia, especially for patients aged 65-74 years.

Major finding: Patients with osteosarcopenia had a higher risk of frailty vs. those with osteoporosis alone (odds ratio [OR], 2.33; P = .028). BMI (per 1 kg/m² decrease) seemed to be the strongest factor associated with osteosarcopenia risk (adjusted OR [aOR], 1.71; P less than .01). In patients aged 65-74 years, estimated glomerular filtration rate (per 10 mL/min/1.73m² decrease) and glycated hemoglobin (per 1% decrease) were identified as independent predictors of osteosarcopenia (aOR, 1.75; P = .01 and aOR, 5.01; P = .01, respectively).

Study details: The data come from a retrospective study of 276 patients with postmenopausal osteoporosis (osteoporosis alone: n=222 and osteosarcopenia: n=54).

Disclosures: The study was supported by grants awarded to Dr. Koji Ishikawa by KAKENHI and Grant of Japan Orthopaedics and Traumatology Research Foundation. The authors declared no conflicts of interest.

Source: Okamura H et al. PLoS One. 2020 Aug 7. doi: 10.1371/journal.pone.0237454.

Key clinical point: Postmenopausal osteoporotic women with low body mass index (BMI) have a higher risk of developing osteosarcopenia. Moreover, appropriate assessments, including the presence of comorbidities, will help in identifying patients at a greater risk of developing osteosarcopenia, especially for patients aged 65-74 years.

Major finding: Patients with osteosarcopenia had a higher risk of frailty vs. those with osteoporosis alone (odds ratio [OR], 2.33; P = .028). BMI (per 1 kg/m² decrease) seemed to be the strongest factor associated with osteosarcopenia risk (adjusted OR [aOR], 1.71; P less than .01). In patients aged 65-74 years, estimated glomerular filtration rate (per 10 mL/min/1.73m² decrease) and glycated hemoglobin (per 1% decrease) were identified as independent predictors of osteosarcopenia (aOR, 1.75; P = .01 and aOR, 5.01; P = .01, respectively).

Study details: The data come from a retrospective study of 276 patients with postmenopausal osteoporosis (osteoporosis alone: n=222 and osteosarcopenia: n=54).

Disclosures: The study was supported by grants awarded to Dr. Koji Ishikawa by KAKENHI and Grant of Japan Orthopaedics and Traumatology Research Foundation. The authors declared no conflicts of interest.

Source: Okamura H et al. PLoS One. 2020 Aug 7. doi: 10.1371/journal.pone.0237454.

Key clinical point: Asthma is associated with an increased risk of osteoporosis and fragility fractures (FF), particularly vertebral and humerus fractures.

Major finding: The risk of osteoporosis and FF was higher in asthma vs. non-asthma group (adjusted hazard ratio [aHR]: 1.18 and 1.12, respectively). The effect was stronger in younger age groups (P_interaction less than .0001). Forearm-wrist (aHR, 1.21) and vertebra (aHR, 1.19) were the sites associated with a higher risk. Among patients with asthma, a single oral corticosteroid course increased the risk of osteoporosis, and greater use of inhaled corticosteroids increased the risk of both bone diseases.

Study details: This population-based matched cohort study included 138,123 patients with asthma and 520,626 age-, sex-, and practice-matched people without asthma using data from the U.K. Clinical Practice Research Datalink.

Disclosures: The study was funded by a research grant from the British Medical Association. The authors declared no conflicts of interest.

Source: Chalitsios CV et al. Eur Respir J. 2020 Aug 6. doi: 10.1183/13993003.01251-2020.

Key clinical point: Asthma is associated with an increased risk of osteoporosis and fragility fractures (FF), particularly vertebral and humerus fractures.

Major finding: The risk of osteoporosis and FF was higher in asthma vs. non-asthma group (adjusted hazard ratio [aHR]: 1.18 and 1.12, respectively). The effect was stronger in younger age groups (P_interaction less than .0001). Forearm-wrist (aHR, 1.21) and vertebra (aHR, 1.19) were the sites associated with a higher risk. Among patients with asthma, a single oral corticosteroid course increased the risk of osteoporosis, and greater use of inhaled corticosteroids increased the risk of both bone diseases.

Study details: This population-based matched cohort study included 138,123 patients with asthma and 520,626 age-, sex-, and practice-matched people without asthma using data from the U.K. Clinical Practice Research Datalink.

Disclosures: The study was funded by a research grant from the British Medical Association. The authors declared no conflicts of interest.

Source: Chalitsios CV et al. Eur Respir J. 2020 Aug 6. doi: 10.1183/13993003.01251-2020.

Key clinical point: Asthma is associated with an increased risk of osteoporosis and fragility fractures (FF), particularly vertebral and humerus fractures.

Major finding: The risk of osteoporosis and FF was higher in asthma vs. non-asthma group (adjusted hazard ratio [aHR]: 1.18 and 1.12, respectively). The effect was stronger in younger age groups (P_interaction less than .0001). Forearm-wrist (aHR, 1.21) and vertebra (aHR, 1.19) were the sites associated with a higher risk. Among patients with asthma, a single oral corticosteroid course increased the risk of osteoporosis, and greater use of inhaled corticosteroids increased the risk of both bone diseases.

Study details: This population-based matched cohort study included 138,123 patients with asthma and 520,626 age-, sex-, and practice-matched people without asthma using data from the U.K. Clinical Practice Research Datalink.

Disclosures: The study was funded by a research grant from the British Medical Association. The authors declared no conflicts of interest.

Source: Chalitsios CV et al. Eur Respir J. 2020 Aug 6. doi: 10.1183/13993003.01251-2020.